| Theme | PPI Therapy | |
|---|---|---|
| Title | Long-Term Treatment with PPI in Relation to CYP2C19 Polymorphism | |
| Publish Date | 2002/02 | |
| Author | Takahisa Furuta | First Department of Medicine, Hamamatsu University School of Medicine (Laboratoly of Molecular Pharmacology, National Cancer Institute, NIH) |
| Author | Naohito Shirai | First Department of Medicine, Hamamatsu University School of Medicine |
| [ Summary ] | Effects of proton pump inhibitors on gastric acid secretion depend significantly on CYP2C19 genotype status. After long term treatment with a PPI, serum levels in gastrin (used as a marker of acid inhibition) and chromogranin A (used as a marker of hyper plasia of ECL cells) in those groups with heterozygous extensive metabolizers (hetEM) or poor metabolizers(PM), CYP2C19 genotypes were significantly higher in comparison to those of the homozygous extensive metabolizer(homEM) genotype group. Serum Vitamin B12 and pepsinogen I levels in the hetEM and PM groups were significantly lower than those of the homEM group inlong term therapy with a PPI. Changes in mucosal morphology and serum VitB12 during long-term treatment with a PPI are assumed to be dependent on CYP2C19 genotype status. A genotyping test for CYP2C19 could provide useful and important information for long-term treatment with a PPI. | |